Stockscreener 앱 받기
9.41
5.14%
0.46
시간 외 거래:
9.20
-0.21
-2.23%
전일 마감가:
$8.95
열려 있는:
$9.25
하루 거래량:
1.59M
Relative Volume:
2.93
시가총액:
$507.43M
수익:
$27.46M
순이익/손실:
$-46.05M
주가수익비율:
-7.2946
EPS:
-1.29
순현금흐름:
$-33.83M
1주 성능:
+0.86%
1개월 성능:
+8.66%
6개월 성능:
+7.42%
1년 성능:
+115.83%
1일 변동 폭
$9.00
$9.625
1주일 범위
$8.58
$9.625
52주 변동 폭
$4.20
$9.76
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
명칭
Zevra Therapeutics Inc
전화
(321) 939-3416
주소
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
ZVRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
9.41 | 507.43M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-08 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 개시 | Guggenheim | Buy |
| 2024-09-24 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-24 | 재확인 | Maxim Group | Buy |
| 2024-04-02 | 재확인 | Maxim Group | Buy |
| 2024-03-12 | 개시 | William Blair | Outperform |
| 2023-03-17 | 개시 | Maxim Group | Buy |
모두보기
Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스
Zevra Therapeutics’ SWOT analysis: strong MIPLYFFA launch boosts stock outlook - Investing.com
Cantor Fitzgerald Forecasts ZVRA FY2026 Earnings - Defense World
Squarepoint Ops LLC Purchases 4,384 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Trend Tracker for (ZVRA) - news.stocktradersdaily.com
Bank of America Corp DE Increases Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Nuveen Asset Management LLC Reduces Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
ZVRAForm DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material - mx.advfn.com
BNP Paribas Financial Markets Buys New Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
ProShare Advisors LLC Makes New Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Millennium Management LLC - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 6,877 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Deutsche Bank AG - Defense World
Zevra Therapeutics confirms board members through stockholder vote By Investing.com - Investing.com South Africa
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders - The Manila Times
Zevra Announces Final Results of 2025 Annual Meeting of Stockhol - GuruFocus
Zevra Therapeutics Elects New Directors at Annual Meeting - TipRanks
Zevra Therapeutics confirms board members through stockholder vote - Investing.com
Zevra Stockholders Overwhelmingly Reject Opposition, Back Current Board with 74% Support - Stock Titan
D. E. Shaw & Co. Inc. Purchases Shares of 25,075 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Trading (ZVRA) With Integrated Risk Controls - news.stocktradersdaily.com
Zevra Therapeutics’ SWOT analysis: rare disease focus drives stock potential By Investing.com - Investing.com Nigeria
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT - Insider Monkey
Zevra Therapeutics’ SWOT analysis: rare disease focus drives stock potential - Investing.com
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Buy” by Analysts - Defense World
Wall Street Zen Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to “Buy” - Defense World
Northern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Cashes in on First FDA-Approved NPC Treatment with PRV - Genetic Engineering and Biotechnology News
Revenues Tell The Story For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) As Its Stock Soars 26% - simplywall.st
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, - GlobeNewswire
Zevra Therapeutics ISS, Glass Lewis & Egan-Jones Recommend Zevra Stockholders Vote For Co's Director Nominees - marketscreener.com
ZVRA Receives Proxy Advisory Firms' Recommendations for Annual Meeting | ZVRA Stock News - GuruFocus
All Three Leading Proxy Advisory FirmsISS, Glass Lewis, and Egan-JonesRecommend Zevra Stockholders Vote FOR the Company's Director Nominees - The Manila Times
Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst - Defense World
Price T Rowe Associates Inc. MD Purchases 6,966 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Cantor Fitzgerald Brokers Boost Earnings Estimates for ZVRA - Defense World
What is William Blair’s Estimate for ZVRA Q1 Earnings? - Defense World
Zevra Therapeutics signals accelerated MIPLYFFA adoption and $148.3M capital infusion while expanding global reach - MSN
Q2 EPS Forecast for Zevra Therapeutics Lifted by Analyst - Defense World
Cantor Fitzgerald Reaffirms Overweight Rating for Zevra Therapeutics (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics Shines in Earnings Call with MIPLYFFA Success - TipRanks
With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics (ZVRA) Reports Strong Q1 Performance, Bolstered by Capital Infusion - GuruFocus
ZVRA Stock Update: Cantor Fitzgerald Reiterates Overweight Ratin - GuruFocus
Breaking Down Zevra Therapeutics: 6 Analysts Share Their Views - Benzinga
ZVRA Stock Update: Cantor Fitzgerald Reiterates Overweight Rating | ZVRA Stock News - GuruFocus
Zevra Therapeutics (ZVRA) Stock Jumps on Strong Q1 Results: What's Going On? - Benzinga
Zevra Therapeutics (ZVRA) Target Price Increased by Analyst | ZV - GuruFocus
Promising Outlook for Zevra Therapeutics: Buy Rating Driven by Strong Miplyffa Launch and Robust Financial Performance - TipRanks
Zevra Therapeutics price target raised to $19 from $18 at Citizens JMP - TipRanks
Zevra Therapeutics Inc (ZVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):